NCT06412848Completed
JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study
A Multicenter, Retrospective, Observational Study of Avelumab Maintenance and Subsequent Therapies in Japanese Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Source: ClinicalTrials.gov · Last updated 11 Aug 2026
Brief summary (registry, in English)
This study is a multicenter, non-interventional, retrospective, medical chart review of locally advanced or metastatic (la/m) Urothelial Cancer UC participants who were prescribed avelumab as first line maintenance therapy after a platinum-based chemotherapy. This study aims to understand the index date (i.e., at the initiation of avelumab maintenance therapy) demographics and clinical characteristics of participants with locally advanced/metastatic Urothelial Carcinoma in Japan, and to describe their treatment patterns and outcomes.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 360 (actual)
- First submitted
- 23 Apr 2024
- Start date
- 9 May 2024
- Primary completion date
- 30 Jun 2026
- Lead sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Diseases
- Bladder cancer
- NCT number
- NCT06412848
What you commit to
- Study type: Observational
- Participants enrolled: 360
- From 9 May 2024 to the primary completion date, 30 Jun 2026
- 26 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Participant participated in a clinical trial in la/m UC during the study periods.
Who the study is looking for
- Participants diagnosed with locally advanced/metastatic urothelial carcinoma (la/m UC) before receiving avelumab first line maintenance therapy
- Participants with la/m UC (irrespective of tumor histology) whose disease has not progressed (ongoing stable disease, partial response, or complete response) following completion of first line PBCT and who has been treated with avelumab
- Participants who has been started avelumab first line maintenance therapy for la/m UC from 24 Feb 2021 (date of approval for UC) to 6 months before the date of approval of implementation of this study at each site
- Participants aged \>= 18 years old at index date
- Other protocol defined inclusion criteria could apply
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (26)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Akita University Hospital Coordinator of this site? Confirm its status | Akita | Japan | Unknown status |
| Juntendo University Hospital Coordinator of this site? Confirm its status | Bunkyō City | Japan | Unknown status |
| Nippon Medical School Hospital Coordinator of this site? Confirm its status | Bunkyo-ku | Japan | Unknown status |
| National Cancer Center Hospital Coordinator of this site? Confirm its status | Chuo Ku | Japan | Unknown status |
| Kyushu Cancer Center Coordinator of this site? Confirm its status | Fukuoka | Japan | Unknown status |
| Saitama Medical University International Medical Center Coordinator of this site? Confirm its status | Hidaka | Japan | Unknown status |
| Hirosaki University Hospital Coordinator of this site? Confirm its status | Hirosaki | Japan | Unknown status |
| Nara Medical University Hospital Coordinator of this site? Confirm its status | Kashihara | Japan | Unknown status |
| St. Marianna University Hospital Coordinator of this site? Confirm its status | Kawasaki | Japan | Unknown status |
| Kagawa University Hospital Coordinator of this site? Confirm its status | Kita-gun | Japan | Unknown status |
| Kobe University Hospital Coordinator of this site? Confirm its status | Kobe | Japan | Unknown status |
| Kumamoto University Hospital Coordinator of this site? Confirm its status | Kumamoto | Japan | Unknown status |
| Kurume University Hospital Coordinator of this site? Confirm its status | Kurume | Japan | Unknown status |
| University Hospital Kyoto Prefectural University of Medicine Coordinator of this site? Confirm its status | Kyoto | Japan | Unknown status |
| Kyoto University Hospital Coordinator of this site? Confirm its status | Kyoto | Japan | Unknown status |
| Osaka International Cancer Institute Coordinator of this site? Confirm its status | Osaka | Japan | Unknown status |
| Kitasato University Hospital Coordinator of this site? Confirm its status | Sagamihara | Japan | Unknown status |
| Sapporo Medical University Hospital Coordinator of this site? Confirm its status | Sapporo | Japan | Unknown status |
| Hokkaido University Hospital Coordinator of this site? Confirm its status | Sapporo | Japan | Unknown status |
| Kindai University Hospital Coordinator of this site? Confirm its status | Sayama | Japan | Unknown status |
| Iwate Medical University Hospital Coordinator of this site? Confirm its status | Shiwa-gun | Japan | Unknown status |
| Teikyo University Hospital Coordinator of this site? Confirm its status | tabashi City | Japan | Unknown status |
| Tokushima University Hospital Coordinator of this site? Confirm its status | Tokushima | Japan | Unknown status |
| Ehime University Hospital Coordinator of this site? Confirm its status | Tōon | Japan | Unknown status |
| Toyama University Hospital Coordinator of this site? Confirm its status | Toyama | Japan | Unknown status |
| Yamagata University Hospital Coordinator of this site? Confirm its status | Yamagata | Japan | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.